Addressing Toxicities of BCMA-Targeted Therapy for Multiple Myeloma

Adam Cohen, MD, discusses the adverse events of concern associated with B-cell maturation antigen–targeted therapies for relapsed/refractory multiple myeloma.

Read the full article here

Related Articles